These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 36381104)

  • 1. Sarcopenia in Chronic Liver Disease: A Metabolic Perspective.
    Kumar R; Prakash SS; Priyadarshi RN; Anand U
    J Clin Transl Hepatol; 2022 Dec; 10(6):1213-1222. PubMed ID: 36381104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcopenia in chronic liver disease: mechanisms and countermeasures.
    Allen SL; Quinlan JI; Dhaliwal A; Armstrong MJ; Elsharkawy AM; Greig CA; Lord JM; Lavery GG; Breen L
    Am J Physiol Gastrointest Liver Physiol; 2021 Mar; 320(3):G241-G257. PubMed ID: 33236953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcopenia from mechanism to diagnosis and treatment in liver disease.
    Dasarathy S; Merli M
    J Hepatol; 2016 Dec; 65(6):1232-1244. PubMed ID: 27515775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cause and management of muscle wasting in chronic liver disease.
    Dasarathy S
    Curr Opin Gastroenterol; 2016 May; 32(3):159-65. PubMed ID: 26974417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarcopenia: Ammonia metabolism and hepatic encephalopathy.
    Jindal A; Jagdish RK
    Clin Mol Hepatol; 2019 Sep; 25(3):270-279. PubMed ID: 31006226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarcopenia in cirrhosis: from pathogenesis to interventions.
    Ebadi M; Bhanji RA; Mazurak VC; Montano-Loza AJ
    J Gastroenterol; 2019 Oct; 54(10):845-859. PubMed ID: 31392488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperammonemia and proteostasis in cirrhosis.
    Dasarathy S; Hatzoglou M
    Curr Opin Clin Nutr Metab Care; 2018 Jan; 21(1):30-36. PubMed ID: 29035972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of l-leucine in cirrhosis.
    Davuluri G; Krokowski D; Guan BJ; Kumar A; Thapaliya S; Singh D; Hatzoglou M; Dasarathy S
    J Hepatol; 2016 Nov; 65(5):929-937. PubMed ID: 27318325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of lithocholic acid with skeletal muscle hypertrophy through TGR5-IGF-1 and skeletal muscle mass in cultured mouse myotubes, chronic liver disease rats and humans.
    Tamai Y; Eguchi A; Shigefuku R; Kitamura H; Tempaku M; Sugimoto R; Kobayashi Y; Iwasa M; Takei Y; Nakagawa H
    Elife; 2022 Oct; 11():. PubMed ID: 36206032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Treatment Options for Sarcopenia in Chronic Liver Disease.
    Kim Y
    Life (Basel); 2021 Mar; 11(3):. PubMed ID: 33803020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease-related fibrosis and sarcopenia: An altered liver-muscle crosstalk leading to increased mortality risk.
    Kuchay MS; Martínez-Montoro JI; Kaur P; Fernández-García JC; Ramos-Molina B
    Ageing Res Rev; 2022 Sep; 80():101696. PubMed ID: 35843589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of L-branched-chain amino acids and L-leucine on malnutrition, sarcopenia, and other outcomes in patients with chronic liver disease.
    Dos Santos ALS; Anastácio LR
    Expert Rev Gastroenterol Hepatol; 2021 Feb; 15(2):181-194. PubMed ID: 32993404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Roles of Non-Pharmacologic and Emerging Pharmacologic Management of Non-alcoholic Fatty Liver Disease and Sarcopenia: A Narrative Review.
    Rivera FB; Adizas A; Cubarrubias D; Bantayan NR; Choi S; Carado GP; Yu MG; Lerma E; Vijayaraghavan K
    J ASEAN Fed Endocr Soc; 2024; 39(1):84-94. PubMed ID: 38863907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of chronic liver disease with bone diseases and muscle weakness.
    Saeki C; Saito M; Tsubota A
    J Bone Miner Metab; 2024 Jul; 42(4):399-412. PubMed ID: 38302761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective Effect of Angiotensin 1-7 on Sarcopenia Induced by Chronic Liver Disease in Mice.
    Aguirre F; Abrigo J; Gonzalez F; Gonzalez A; Simon F; Cabello-Verrugio C
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32485991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarcopenia in hiding: The risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis.
    Bhanji RA; Narayanan P; Allen AM; Malhi H; Watt KD
    Hepatology; 2017 Dec; 66(6):2055-2065. PubMed ID: 28777879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcopenia Is a Cause and Consequence of Metabolic Dysregulation in Aging Humans: Effects of Gut Dysbiosis, Glucose Dysregulation, Diet and Lifestyle.
    Daily JW; Park S
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What Does Sarcopenia Have to Do with Nonalcoholic Fatty Liver Disease?
    Ferenc K; Jarmakiewicz-Czaja S; Filip R
    Life (Basel); 2023 Dec; 14(1):. PubMed ID: 38255652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis.
    Tsien C; Davuluri G; Singh D; Allawy A; Ten Have GA; Thapaliya S; Schulze JM; Barnes D; McCullough AJ; Engelen MP; Deutz NE; Dasarathy S
    Hepatology; 2015 Jun; 61(6):2018-29. PubMed ID: 25613922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Mechanisms and Treatment of Sarcopenia in Liver Disease: A Review of Current Knowledge.
    Kamimura H; Sato T; Natsui K; Kobayashi T; Yoshida T; Kamimura K; Tsuchiya A; Murayama T; Yokoyama J; Kawai H; Takamura M; Terai S
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.